サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363121

結核診断の市場規模、シェア、動向分析レポート：検査タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 110 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
結核診断の市場規模、シェア、動向分析レポート：検査タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月22日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

結核診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の結核診断市場規模は2023年から2030年にかけてCAGR 5.2％を記録し、2030年までに33億4,000万米ドルに達すると予測されています。

インターフェロン-ガンマ放出アッセイ（IGRA）、血清学的手法、核酸検査などの高度な診断手法の登場が、診断薬の高い使用率につながっています。さらに、抗原アッセイなどのPOC（Point of Care）技術も結核診断率を高めています。

POC診断を含むこれらの高度な方法は、手頃な価格で正確かつ簡便であり、迅速な結果が得られます。さらに、結核の負担増が市場成長の主な要因となっています。世界保健機関（WHO）によると、2014年の結核患者の世界推計は約960万人でした。この高い有病率により、政府、ヘルスケア機関、調査機関、市場関係者は、この感染症の発生を抑制するための努力を開始しました。

高負担地域における検診率の上昇、手頃な価格の診断薬、高度な調査手法、迅速な臨床判断、死亡率の低下が開発の焦点となっています。予防的・治療的診断率の向上は、こうした取り組みの最終的な成果です。このため、診断検査に対する需要が急増し、結核診断市場が拡大しています。

結核診断市場レポートハイライト

  • 検査タイプに基づき、結核診断市場はX線検査法、検査室診断法、核酸検査法、ファージアッセイ、潜伏感染検出法、サイトカイン検出アッセイ、薬剤耐性検出法に区分されます。
  • 診断ラボラトリー検査は、コスト効率が高く、実施が容易であるため、2015年の市場シェアは38.0%で、検査タイプセグメントを支配しました。診断ラボ検査には塗抹顕微鏡検査と培養ベースの検査が含まれます。高負担地域では、先進技術を取り入れる財政的・技術的能力がないため、これらの手法に依存しており、診断ラボ検査分野の成長に寄与しています。
  • しかしながら、精度の低下と処理時間の長さが、この診断法における制限要因となっています。そのため、ヘルスケア機関は発展途上地域で先進技術の導入に努めています。
  • その結果、核酸検査セグメントと、皮膚検査やIGRAを含む潜在感染症検出セグメントは、収益性の高い成長率を示す可能性が高いです。これらの方法は、前述の制限を克服することにより、診断法の手頃な価格、処理時間、精度を向上させる。
  • 結核における薬剤耐性は、誤った薬剤レジメンや誤った剤形による不適切な治療が、治療中の結核患者における薬剤耐性の発現につながるため、ヘルスケア専門家にとって主要な懸念事項の1つです。それゆえ、薬剤耐性検出分野もまた、有利な成長を示すと予測されています。
  • 膨大な人口と高い結核罹患率を有するアジア太平洋地域は、2015年に世界の結核診断市場を独占しました。WHOによると、インド、中国、アフガニスタン、インドネシアなどの国々は、この伝染病をコントロールするための優先地域です。
  • 結核検査市場のプレーヤーには、Thermo Fisher Scientific, Inc.、Hologic Corporation、Abbott Laboratories、Alere, Inc.、Becton, Dickinson and Company、F. Hoffmann-La Roche AG、bioMerieux SA、Sanofi、Cepheid、Hain Lifescience GmbH、QIAGENが含まれます。
  • 新製品の発売、コラボレーション、M&A、地域拡大は、これらの業界プレーヤーが行う主要な戦略的イニシアチブです。
  • 例えば、2016年7月、bioMerieuxは、結核の同定のための新規のCEマーク付きデータベースと試薬キットVITEK MSを発売しました。この新製品の発売は、同社の市場シェア拡大に貢献すると期待されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 結核診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 結核診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 結核診断：検査タイプの推定・動向分析

  • 結核診断市場：重要なポイント
  • 結核診断市場：動向と市場シェア分析、2022年および2030年
  • 放射線撮影法
  • 診断検査法
  • 核酸検査
  • ファージアッセイ
  • 潜伏感染の検出（皮膚テストおよびIGRA）
  • サイトカイン検出アッセイ
  • 薬剤耐性の検出（DST）
  • その他

第5章 結核診断：最終用途別推定・動向分析

  • 結核診断市場：重要なポイント
  • 結核診断市場：動向と市場シェア分析、2022年および2030年
  • 診断ラボ
  • 病院とクリニック
  • その他

第6章 結核診断市場：地域別推定・動向分析

  • 地域別の展望
  • 地域別の結核診断市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific Inc.
    • BioMerieux SA
    • Hain Lifescience GmbH
    • QIAGEN GmbH
    • Cepheid
    • Hologic, Inc.
    • BD
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 3 North America tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 North America tuberculosis diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 6 U.S. tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 Canada tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Europe tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Europe tuberculosis diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Germany tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 UK tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 UK tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 France tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 France tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Italy tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 19 Italy tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 Spain tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Sweden tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Sweden tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Norway tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 Norway tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Denmark tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Denmark tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific tuberculosis diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 China tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Japan tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Japan tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 India tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 India tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Australia tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Australia tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Thailand tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 Thailand tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 South Korea tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 44 Latin America tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 Latin America tuberculosis diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 47 Brazil tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Mexico tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 Argentina tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa tuberculosis diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 56 South Africa tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 UAE tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait tuberculosis diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait tuberculosis diagnostics market, by end-use, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Tuberculosis diagnostics: Market outlook
  • Fig. 9 Tuberculosis diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Tuberculosis diagnostics market driver impact
  • Fig. 15 Tuberculosis diagnostics market restraint impact
  • Fig. 16 Tuberculosis diagnostics market strategic initiatives analysis
  • Fig. 17 Tuberculosis diagnostics market: Test type movement analysis
  • Fig. 18 Tuberculosis diagnostics market: Test type outlook and key takeaways
  • Fig. 19 Radiographic method market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Diagnostic laboratory methods market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Nucleic acid testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Phage assay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Detection of latent infection (skin test & IGRA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Cytokine detection assay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Detection of drug resistance (DST) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Other methods market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Tuberculosis diagnostics market: End-use movement analysis
  • Fig. 28 Tuberculosis diagnostics market: End-use outlook and key takeaways
  • Fig. 29 Diagnostic laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Global tuberculosis diagnostics market: Regional movement analysis
  • Fig. 33 Global tuberculosis diagnostics market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-098-9

Tuberculosis Diagnostics Market Growth & Trends:

The global tuberculosis diagnostics market size is expected to reach USD 3.34 billion by 2030, registering a CAGR of 5.2% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Tuberculosis Diagnostics Market Report Highlights:

  • Based on tests type, the tuberculosis diagnostics market is segmented into radiographic methods, diagnostic laboratory methods, nucleic acid testing, phage assay, detection of latent infection, cytokine detection assay, and detection of drug resistance.
  • Diagnostic laboratory tests dominated the test type segment with 38.0% market share in 2015 as they are cost efficient and easy-to-perform. Diagnostic laboratory tests include smear microscopy and culture-based tests. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies thus contributing to the growth of the diagnostic laboratory tests segment.
  • However, compromised accuracy and the longer processing time are the limiting factor for the diagnostics. Hence, healthcare agencies are striving to implement advanced techniques in the developing regions.
  • As a result, nucleic acid tests segment and the latent infection detection segment, which includes skin tests and IGRA, are likely to exhibit a profitable growth rate. These methods overcome the aforementioned limitations thus improving affordability, processing time and accuracy of the diagnostic method.
  • Drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimen and incorrect dosage forms lead to the development of drug resistance in TB patients undergoing treatment. Hence, the drug resistance detection segment is also anticipated to witness lucrative growth.
  • Asia Pacific owing to its huge population base and high burden of TB dominated the global TB diagnostics market in 2015. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for control of this communicable disease.
  • The players in the TB testing market include Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH, and QIAGEN.
  • New product launches, collaboration, mergers & acquisitions, and regional expansion are the key strategic initiatives undertaken by these industry players
  • For instance, in July 2016, bioMerieux launched a novel CE marked database and reagents kit VITEK MS for the identification of TB. This new product launch is anticipated to help the company increase its market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test Type
    • 1.1.2. End-use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Tuberculosis Diagnostics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Tuberculosis Diagnostics: Test Type Estimates & Trend Analysis

  • 4.1. Tuberculosis Diagnostics Market: Key Takeaways
  • 4.2. Tuberculosis Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Radiographic Method
    • 4.3.1. Radiographic method market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Diagnostic Laboratory Methods
    • 4.4.1. Diagnostic laboratory methods market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Nucleic Acid Testing
    • 4.5.1. Nucleic acid testing market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.6. Phage Assay
    • 4.6.1. Phage assay market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.7. Detection of Latent Infection (Skin Test & IGRA)
    • 4.7.1. Detection of latent infection market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.8. Cytokine Detection Assay
    • 4.8.1. Cytokine detection assay market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.9. Detection of Drug Resistance (DST)
    • 4.9.1. Detection of drug resistance (DST) market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.10. Other Methods
    • 4.10.1. Other methods market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Tuberculosis Diagnostics: End-use Estimates & Trend Analysis

  • 5.1. Tuberculosis Diagnostics Market: Key Takeaways
  • 5.2. Tuberculosis Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Diagnostic Laboratories
    • 5.3.1. Diagnostic laboratories market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Tuberculosis Diagnostics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Abbott Laboratories
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Becton, Dickinson and Company
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. F. Hoffmann-La Roche AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Thermo Fisher Scientific Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. BioMerieux SA
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Hain Lifescience GmbH
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. QIAGEN GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Cepheid
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Hologic, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. BD
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives